Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Atherosclerotic Cardiovascular Disease (ASCVD)

In brief

The purpose of the study CTQJ230A12304, is to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) compared to placebo in participants with ASCVD who have elevated lipoprotein(a) (Lp(a)), and who are on background inclisiran treatment for elevated low-density lipoprotein cholesterol (LDL-C).

Key facts

Study ID
NCT06813911
Run by
Novartis Pharmaceuticals
People needed
340
Starts
2025-04-30
Expected to finish
2028-02-29
Last updated by the study team
2026-08-07

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.